FourThought Financial’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

FourThought Financial’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2K	Hold	500	–	–	﹤0.01%	1370
2022 Q2	$2K	Buy	+500	New	+$1.42K	﹤0.01%	1376

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

FourThought Financial's VIRX Position: Q3 2022 in Review

FourThought Financial held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q3 2022 at 500 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

FourThought Financial first reported a position in VIRX in Q2 2022 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2022.

FourThought Financial held 500 shares of Viracta Therapeutics, Inc. Common Stock worth $2K as of Q3 2022.
FourThought Financial left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1370 holding.
FourThought Financial first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2022 and has held it in 2 quarters since.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.